EntroGen, Inc

May 15, 2012

Visit EntroGen at the AACC 2012 Annual Meeting's Clinical Lab Expo

May 4, 2012

BRAF Codon 600 Mutation Analysis Kit Cleared for IVD Use in Europe

EntroGen's BRAF Codon 600 Mutation Analysis Kit now bears a CE-IVD mark obtained under the European Directive on In Vitro Diagnostic Medical Devices.

March 20, 2012

BioSystems S.A. to sell EntroGen products in Argentina.

BioSystems S.A. has signed an exclusive distributor agreement to sell EntroGen products in Argentina.

January 31, 2012

EntroGen receives ISO 13485 certification

EntroGen, Inc has received ISO 13485:2003 certification from NSF for the quality management system of its medical devices. The certification covers design, development, manufacturing and sale of research and diagnostic tools.

August 23, 2011

BÜHLMANN becomes an exclusive distributor of EntroGen's products in Switzerland/Liechtenstein, Austria and France

BÜHLMANN Laboratories AG has signed an exclusive distributor agreement to sell EntroGen products in Switzerland/Liechtenstein, Austria and France.

July 11, 2011

Visit EntroGen at the AMP 2011 Annual Meeting

April 10, 2011

Visit EntroGen at the AACC 2011 Annual Meeting's Clinical Lab Expo

November 29, 2010

AMP becomes an exclusive distributor of EntroGen's products in Germany

Asbach Medical Products GMBH has signed an exclusive distributor agreement to sell EntroGen products in Germany.

September 12, 2010

Zotal Ltd becomes an exclusive distributor of EntroGen's products in Israel

Zotal Ltd has signed an exclusive distributor agreement to sell EntroGen products in Israel.

April 14, 2010

EntroGen Enters Into an Agreement With Childrens Hospital Los Angeles to Develop a Novel Genome-based Test for Ewing's Sarcoma

TARZANA, Calif., Apr 14, 2010 --- Today, EntroGen announced that it has entered into a collaboration and licensing agreement with the Childrens Hospital Los Angeles to develop a molecular diagnostic test for Ewing’s Sarcoma Family of tumors (EFT). The test will be based on a highly specific biomarker discovered at CHLA/USC and will offer oncologists a definitive diagnosis of EFT.

Primary links